Cargando…
Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt
Background. The introduction of MenAfriVac in campaigns targeting people aged 1–29 years across the African meningitis belt has successfully reduced meningitis incidence and carriage due to Neisseria meningitidis group A (MenA). It is important to consider how best to sustain population protection i...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639487/ https://www.ncbi.nlm.nih.gov/pubmed/26553693 http://dx.doi.org/10.1093/cid/civ508 |
_version_ | 1782399921208426496 |
---|---|
author | Karachaliou, Andromachi Conlan, Andrew J. K. Preziosi, Marie-Pierre Trotter, Caroline L. |
author_facet | Karachaliou, Andromachi Conlan, Andrew J. K. Preziosi, Marie-Pierre Trotter, Caroline L. |
author_sort | Karachaliou, Andromachi |
collection | PubMed |
description | Background. The introduction of MenAfriVac in campaigns targeting people aged 1–29 years across the African meningitis belt has successfully reduced meningitis incidence and carriage due to Neisseria meningitidis group A (MenA). It is important to consider how best to sustain population protection in the long term. Methods. We created a mathematical model of MenA transmission and disease to investigate the potential impact of a range of immunization strategies. The model is age structured; includes classes of susceptible, carrier, ill, and immune people (who may be vaccinated or unvaccinated); and incorporates seasonal transmission and a stochastic forcing term that models between year variation in rates of transmission. Model parameters were primarily derived from African sources. The model can describe the typical annual incidence of meningitis in the prevaccine era, with irregular epidemics of varying size. Parameter and structural uncertainty were explored in sensitivity analyses. Results. Following MenAfriVac introduction at high uptake, the model predicts excellent short-term disease control. With no subsequent immunization, strong resurgences in disease incidence were predicted after approximately 15 years (assuming 10 years’ average vaccine protection). Routine immunization at 9 months of age resulted in lower average annual incidence than regular mass campaigns of 1- to 4-year-olds, provided coverage was above approximately 60%. The strategy with the lowest overall average annual incidence and longest time to resurgence was achieved using a combination strategy of introduction into the Expanded Programme on Immunization at 9 months, 5 years after the initial mass campaigns, with a catch-up targeting unvaccinated 1- to 4-year-olds. Conclusions. These results can be used to inform policy recommendations for long-term vaccination strategies with MenAfriVac. |
format | Online Article Text |
id | pubmed-4639487 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-46394872015-11-12 Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt Karachaliou, Andromachi Conlan, Andrew J. K. Preziosi, Marie-Pierre Trotter, Caroline L. Clin Infect Dis The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa Background. The introduction of MenAfriVac in campaigns targeting people aged 1–29 years across the African meningitis belt has successfully reduced meningitis incidence and carriage due to Neisseria meningitidis group A (MenA). It is important to consider how best to sustain population protection in the long term. Methods. We created a mathematical model of MenA transmission and disease to investigate the potential impact of a range of immunization strategies. The model is age structured; includes classes of susceptible, carrier, ill, and immune people (who may be vaccinated or unvaccinated); and incorporates seasonal transmission and a stochastic forcing term that models between year variation in rates of transmission. Model parameters were primarily derived from African sources. The model can describe the typical annual incidence of meningitis in the prevaccine era, with irregular epidemics of varying size. Parameter and structural uncertainty were explored in sensitivity analyses. Results. Following MenAfriVac introduction at high uptake, the model predicts excellent short-term disease control. With no subsequent immunization, strong resurgences in disease incidence were predicted after approximately 15 years (assuming 10 years’ average vaccine protection). Routine immunization at 9 months of age resulted in lower average annual incidence than regular mass campaigns of 1- to 4-year-olds, provided coverage was above approximately 60%. The strategy with the lowest overall average annual incidence and longest time to resurgence was achieved using a combination strategy of introduction into the Expanded Programme on Immunization at 9 months, 5 years after the initial mass campaigns, with a catch-up targeting unvaccinated 1- to 4-year-olds. Conclusions. These results can be used to inform policy recommendations for long-term vaccination strategies with MenAfriVac. Oxford University Press 2015-11-15 2015-11-09 /pmc/articles/PMC4639487/ /pubmed/26553693 http://dx.doi.org/10.1093/cid/civ508 Text en © The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa Karachaliou, Andromachi Conlan, Andrew J. K. Preziosi, Marie-Pierre Trotter, Caroline L. Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt |
title | Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt |
title_full | Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt |
title_fullStr | Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt |
title_full_unstemmed | Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt |
title_short | Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt |
title_sort | modeling long-term vaccination strategies with menafrivac in the african meningitis belt |
topic | The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639487/ https://www.ncbi.nlm.nih.gov/pubmed/26553693 http://dx.doi.org/10.1093/cid/civ508 |
work_keys_str_mv | AT karachaliouandromachi modelinglongtermvaccinationstrategieswithmenafrivacintheafricanmeningitisbelt AT conlanandrewjk modelinglongtermvaccinationstrategieswithmenafrivacintheafricanmeningitisbelt AT preziosimariepierre modelinglongtermvaccinationstrategieswithmenafrivacintheafricanmeningitisbelt AT trottercarolinel modelinglongtermvaccinationstrategieswithmenafrivacintheafricanmeningitisbelt |